Savara investors brace for earnings ahead of key FDA ruling

Savara Inc. is preparing to release its third-quarter earnings report on November 16, just six days before a critical FDA decision regarding its experimental treatment MOLBREEVI. The biotech faces an uncertain future as it awaits the regulatory ruling on the rare lung disease MPA, which has no approved treatments in the United States.

Analysts predict Savara will report a loss of 15.5 cents per share for the quarter, a minor improvement from the 16-cent loss incurred in the previous period. Revenue remains at zero as the company has yet to commercialize any products. The earnings report arrives amidst strong analyst optimism, with all nine covering the stock recommending a buy rating and a consensus price target of $11.06, representing a significant 138% upside from the current $4.64 share price.

However, EPS estimates have decreased by 8% over the past 60 days. H.C. Wainwright initiated coverage of Savara on November 12, expressing confidence that MOLBREEVI could become the first FDA-approved therapy for MPA. The company is focusing its upcoming earnings call on the regulatory review process, cash position, physician engagement, and launch planning.

Citizens analyst Jonathan Wolleben notes that with around 1,000 potential patients and strong physician interest, the consensus sales estimate of $81 million in 2027 will likely be conservative. Savara currently operates at a loss as it prepares for commercialization, experiencing a 29% year-over-year decline in operating income.

The earnings report will provide one of the final updates before the November 22 FDA review date, which could validate the company's $1.25 billion market capitalization or signal a transformation that some analysts believe justifies valuations as high as $2.6 billion.